Fundamental Analysis of NEWAMSTERDAM PHARMA CO NV(NASDAQ:NAMS) stock

Fundamental Rating

Taking everything into account, NAMS scores 2 out of 10 in our fundamental rating. NAMS was compared to 568 industry peers in the Biotechnology industry. NAMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NAMS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NAMS has reported negative net income.

1.2 Ratios

The Return On Assets of NAMS (-16.57%) is better than 80.71% of its industry peers.

NAMS's Return On Equity of -18.48% is amongst the best of the industry. NAMS outperforms 86.37% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.57%
ROE	-18.48%
ROIC	N/A

ROA(3y)-3.89%

ROA(5y)N/A

ROE(3y)-4.3%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NAMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NAMS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NAMS has more shares outstanding

NAMS has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 34.02 indicates that NAMS is not in any danger for bankruptcy at the moment.

NAMS's Altman-Z score of 34.02 is amongst the best of the industry. NAMS outperforms 96.11% of its industry peers.

NAMS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.00, NAMS is in line with its industry, outperforming 50.80% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	34.02

ROIC/WACCN/A

WACC7.18%

2.3 Liquidity

A Current Ratio of 10.15 indicates that NAMS has no problem at all paying its short term obligations.

NAMS's Current ratio of 10.15 is amongst the best of the industry. NAMS outperforms 81.59% of its industry peers.

NAMS has a Quick Ratio of 10.15. This indicates that NAMS is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 10.15, NAMS belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	10.15
Quick Ratio	10.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NAMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -505.51%.

EPS 1Y (TTM)-505.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1283.85%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -55.16% on average over the next years. This is quite bad

The Revenue is expected to grow by 3.57% on average over the next years.

EPS Next Y-1306.89%

EPS Next 2Y-270.75%

EPS Next 3Y-131.89%

EPS Next 5Y-55.16%

Revenue Next Year-87.36%

Revenue Next 2Y-44.48%

Revenue Next 3Y-53.65%

Revenue Next 5Y3.57%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NAMS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NAMS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NAMS's earnings are expected to decrease with -131.89% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-270.75%

EPS Next 3Y-131.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NAMS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEWAMSTERDAM PHARMA CO NV

NASDAQ:NAMS (12/20/2024, 8:26:28 PM)

After market: 25.5 0 (0%)

25.5

+0.04 (+0.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2024-11-06/bmo

Earnings (Next)N/A N/A

Inst Owners72.32%

Inst Owner Change6.03%

Ins Owners0.26%

Ins Owner Change2.76%

Market Cap2.72B

Analysts87.5

Price Target38.12 (49.49%)

Short Float %3.27%

Short Ratio3.18

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)1.01%

PT rev (3m)0.62%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-16.39%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)86.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	27.94
P/FCF	N/A
P/OCF	N/A
P/B	6.45
P/tB	8
EV/EBITDA	N/A

EPS(TTM)-0.95

EYN/A

EPS(NY)-2.15

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0.91

BVpS3.95

TBVpS3.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.57%
ROE	-18.48%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-3.89%

ROA(5y)N/A

ROE(3y)-4.3%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	10.15
Quick Ratio	10.15
Altman-Z	34.02

F-ScoreN/A

WACC7.18%

ROIC/WACCN/A

Cap/Depr(3y)486.97%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-505.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1283.85%

EPS Next Y-1306.89%

EPS Next 2Y-270.75%

EPS Next 3Y-131.89%

EPS Next 5Y-55.16%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-87.36%

Revenue Next 2Y-44.48%

Revenue Next 3Y-53.65%

Revenue Next 5Y3.57%

EBIT growth 1Y-188.3%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5236.6%

EBIT Next 3Y-222.64%

EBIT Next 5Y-118.08%

FCF growth 1Y5851.55%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y5860.95%

OCF growth 3YN/A

OCF growth 5YN/A

NEWAMSTERDAM PHARMA CO NV (NAMS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens